ARL9 and colon adenocarcinoma: The mRNA expression of ARL9 in colon adenocarcinoma patients was divided into low and high expression groups for the GSEA, and the target pathways were selected from the KEGG enrichment results with a false discovery rate (FDR) q value of < 0.05 in the high and low expression groups, respectively, as shown in Table 2; the multi-GSEA is plotted in Fig. 6.